Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo may extend life in tough pancreatic cancer

NCT ID NCT03943667

Completed Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people live longer. The goal was to find a better second-line option for this hard-to-treat cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

  • CH Simone Veil

    Beauvais, France

  • CH de Bayeux

    Bayeux, France

  • CH du Cotentin

    Cherbourg, France

  • CHU Jean Minjoz

    Besançon, France

  • CHU La Timone

    Marseille, France

  • CHU Rouen

    Rouen, France

  • CHU de Saint-Etienne

    Saint-Etienne, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Léon Bérard

    Lyon, France

  • Hospices civils de Lyon

    Lyon, France

  • Hôpital Broussais

    St-Malo, France

  • Hôpital Duchenne

    Boulogne-sur-Mer, France

  • Hôpital Européen de Marseille

    Marseille, France

  • Hôpital Nord Franche Comté

    Montbéliard, France

  • Hôpital Pitié-Salpétrière

    Paris, France

  • Hôpital Saint-Joseph

    Marseille, France

  • Hôpital Saint-Louis

    Paris, 75011, France

  • Hôpital Trousseau

    Tours, France

  • Institut Curie

    Saint-Cloud, France

  • Institut Godinot

    Reims, France

  • Institut Gustave Roussy

    Villejuif, France

  • Institut Mutualiste Montsouris

    Paris, 75014, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut de Cancérologie de l'Ouest

    Saint-Herblain, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.